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Looking forward to another exciting year of Clinical Ophthalmology
Welcome to the ﬁ  rst edition of Clinical Ophthalmology of 2008. This is our second year 
of publication after an extremely busy ﬁ  rst year. We continue to get a huge number of 
submissions and this has accelerated now that the journal is almost completely open 
access. The reasons for this acceleration may be wider access of published articles from 
the journal or may simply be a result of the number of excellent articles that continue 
to be rejected by the more established journals. The latter often cite lack of print space 
as a reason for this rejection – something that we at Clinical Ophthalmology will never 
do. If our peer reviewers feel an article is good enough, then it will be published.
As a testament to this excellence you can browse the current edition and, whatever 
your interests are, you will be sure to ﬁ  nd at least one paper that catches your eye. For 
an up-to-date review of the role of ranibizumab in age-related macular degeneration 
treatment turn to the review by Spitzer and colleagues (2008). To give some hope to 
your patients with homonymous hemianopias, look at the work by Lane and colleagues 
(2008). The thorny issue of raised intraocular pressure after intravitreal triamcinalone 
is discussed by Kocabora and colleagues (2008).
As always, we carry a number of case reports. I have previously discussed the role 
of case reports in journals, but there is little doubt they are popular among readers. This 
may be because they so obviously reﬂ  ect the idiosyncrasies of daily practice. Who 
can resist such titles as ‘Ischemic maculopathy in zidovudine-induced anemia in an 
HIV-positive man’ (Yoganathan & Austin 2008) or ‘Inverse Argyll Robertson pupil in 
Burkitt’s lymphoma’ (Chalam et al 2008), or ‘Experimental effect of retinoic acids on 
apoptosis during the development of diabetic retinopathy’ (Nishikiori et al 2008)?
Finally, those of you who read my last editorial will realize that I am very pleased 
that this edition carries ‘Letters to the Editor’. As I had mentioned excellent letters, 
such as two you will ﬁ  nd in the current edition, represent dynamism in a journal. This 
is something we constantly have and will continue to strive for. So, once again, if 
you have any comments in regard to the papers in this edition – positive, negative, or 
adding further information – please do not hesitate to contact me.
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